Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eli Lilly and Co. | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Eli Lilly and Co.

Greg Plowman, M.D., Ph.D., has been appointed to lead Lilly’s oncology research efforts as the vice president of oncology research, and senior vice president of ImClone Systems research.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Greg Plowman, M.D., Ph.D., has been appointed to lead Lilly’s oncology research efforts as the vice president of oncology research, and senior vice president of ImClone Systems research. Dr. Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone, and will be based at ImClone’s Alexandria Center for Life Science in New York City. He reports to Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories (LRL), and Bernhard Ehmer, M.D., president of ImClone.

“Oncology represents a major area of unmet medical need and rapidly advancing science is driving us to discover new treatments with better efficacy to prolong the survival of the patients we serve,” said Dr. Lundberg. “The introduction of a new oncology research leader across Lilly and ImClone will ensure the pursuit of the right mechanisms, therapeutic agents and tailoring strategies across our oncology business. Greg’s position is unique and his experience makes him an ideal choice for this new position.”

Most recently, Dr. Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He directed research efforts in anti-angiogenesis, biomedical imaging, and tumor biology, and was responsible for building a pipeline of new agents for treatment of cancer and ocular disease. He has 25 years of experience in cancer research including leadership roles at Oncogen, Sugen, Exelixis and Genentech (now Bristol-Myers Squibb, Pharmacia and Roche).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters